Although nanoparticle strategies targeting leukemia or lymphoma-specific markers such as CD19 and CD20 have been developed for other agents [100] and melittin-derived peptides have been incorporated into nanocomplexes for siRNA delivery in vitro [101], dedicated studies evaluating melittin-loaded formulations—such as liposomes or polymeric nanoparticles—for systemic delivery in leukemia or lymphoma models in vivo remain notably scarce in the recent literature. The gene discussed is CD19; the disease is leukemia.